Being on hormonal therapy reflects the ER/PR status of the participants, with hormonal therapy being prescribed after the completion of initial cancer treatment to those who are ER+ and/or PR+, and has been proven to reduce the risk of a cancer recurrence or the development of a new breast cancer. The gene discussed is ESR1; the disease is cancer.